ERBB2 and neoplasm: Despite playing a smaller role in overall tumor progression compared to the PI3K/Akt pathway, RAS/RAF/MEK/ERK acts as an important mediator of drug resistance in HER2+ BC and therapeutic targeting of this pathway may allow for overcoming resistance to HER2 targeting therapies.